STUDY RESULTS WITH XYWAV
Study results for XYWAV in adults with Idiopathic Hypersomnia (IH)
A clinical study of nightly XYWAV showed that, compared to placebo (a treatment that is inactive), XYWAV:
Helped treat excessive daytime sleepiness
Helped with overall Idiopathic Hypersomnia symptoms (patient reported)
Helped with the severity and frequency of Idiopathic Hypersomnia symptoms like long sleep time, cognitive impairment, and sleep inertia
What changes in excessive daytime sleepiness were seen in people during the XYWAV clinical study?
- Excessive daytime sleepiness (EDS) is measured by a screener called the Epworth Sleepiness Scale (ESS).
- The ESS measures EDS on a scale from
0 to 24.
Note: The information collected during the first part of the study was not meant to measure how well XYWAV worked.
Stable dose = the dose of XYWAV that worked best for each person.
Results shown here used average scores, which were then rounded up or down. That’s why the difference between scores may not always appear to add up.
Not sure of your ESS score?
Find out your level of daytime sleepiness and be sure to share your results with your doctor.
Source: Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep.1991;14(6):540-545.
The Epworth Sleepiness Scale (ESS) is intended to measure EDS, a symptom of Idiopathic Hypersomnia. It is not intended to make an Idiopathic Hypersomnia diagnosis.
What changes in overall Idiopathic Hypersomnia symptoms were seen in people during the XYWAV clinical study?
- The Patient Global Impression of Change (PGIc) screener was used to measure how well XYWAV helps treat symptoms of Idiopathic Hypersomnia overall.
- The PGIc asked participants to rate how their Idiopathic Hypersomnia felt using a
7-point scale ranging from “very much improved” to “very much worse.”
Worsening was defined as “minimally, much worse, or very much worse” Idiopathic Hypersomnia overall. Improvement was defined as “minimally, much improved, or very much improved” Idiopathic Hypersomnia overall.
What changes in Idiopathic Hypersomnia symptoms were seen in people during the XYWAV clinical study?
- Severity and frequency of Idiopathic Hypersomnia symptoms is measured by a screener called the Idiopathic Hypersomnia Severity Scale (IHSS).
- The IHSS is a unique screener—it is the only one validated to measure Idiopathic Hypersomnia symptoms.
- The IHSS asks participants to answer 14 questions related to the frequency and intensity of a range of symptoms—including excessive sleepiness, long sleep time, cognitive impairment, and sleep inertia.
- The IHSS measures frequency and severity of Idiopathic Hypersomnia symptoms on a scale of 0 to 50.
Note: The information collected during the first part of the study was not meant to measure how well XYWAV worked.
Stable dose = the dose of XYWAV that worked best for each person.
Results shown here used average scores, which were then rounded up or down. That’s why the difference between scores may not always appear to add up.
Do you know your IHSS score?
Rate the severity and frequency of your Idiopathic Hypersomnia symptoms and be sure to share your results with your doctor.
Source: Dauvilliers Y, Evangelista E, Barateau L, et al. Measurement of symptoms in idiopathic hypersomnia: the Idiopathic Hypersomnia Severity Scale. Neurology. 2019;92(15):e1754-e1762.
The Idiopathic Hypersomnia Severity Scale is intended to measure the frequency and severity of Idiopathic Hypersomnia symptoms. It is not intended to make an Idiopathic Hypersomnia diagnosis.
